Next Article in Journal
Triple Test Plus Rapid Cognitive Screening Test: A Combination of Clinical Signs and A Tool for Cognitive Assessment in Older Adults
Previous Article in Journal
Who Is Classified as Untestable on Brief Cognitive Screens in an Acute Stroke Setting?
Open AccessArticle

Development of a Highly Sensitive Technique for Capturing Renal Cell Cancer Circulating Tumor Cells

1
Department of Urology, Showa University, Tokyo 142-8666, Japan
2
Department of Physiology, School of Medicine, Showa University, Tokyo 142-8666, Japan
3
Ishii-clinic Kyobashi Edogrand, Tokyo 104-0031, Japan
*
Author to whom correspondence should be addressed.
Diagnostics 2019, 9(3), 96; https://doi.org/10.3390/diagnostics9030096
Received: 29 July 2019 / Revised: 13 August 2019 / Accepted: 13 August 2019 / Published: 14 August 2019
(This article belongs to the Special Issue Liquid Biopsy in Solid Tumor Oncology)
purpose: Liquid biopsy is becoming increasingly important as a guide for selecting new drugs and determining their efficacy. In urological cancer, serum markers for renal cell and urothelial cancers has made the development of liquid biopsy for these cancers strongly desirable. Liquid biopsy is less invasive than conventional tissue biopsy is, enabling frequent biopsies and, therefore, is considered effective for monitoring the treatment course. Circulating tumor cells (CTCs) are a representative liquid biopsy specimen. In the present study, we focused on developing our novel technology for capturing renal cell cancer (RCC)-CTCs using an anti-G250 antibody combined with new devices. Basic experiments of our technology showed that it was possible to detect RCC-CTC with a fairly high accuracy of about 95%. Also, RCC-CTC was identified in the peripheral blood of actual RCC patients. Additionally, during the treatment course of the RCC patient, change in the number of RCC-CTC was confirmed in one case. We believe that the technology we developed will be useful for determining the treatment efficacy and drug selection for the treatment of renal cell cancer (RCC). In order to solve issues such as thresholds setting of this technology, large-scale clinical trials are expected. View Full-Text
Keywords: circulating tumor cells; renal cell carcinoma; G250 antigen circulating tumor cells; renal cell carcinoma; G250 antigen
Show Figures

Figure 1

MDPI and ACS Style

Naoe, M.; Kusaka, C.; Ohta, M.; Hasebe, Y.; Unoki, T.; Shimoyama, H.; Nakasato, T.; Oshinomi, K.; Morita, J.; Fuji, K.; Ogawa, Y.; Tsukada, M.; Sunagawa, M.; Ishii, H. Development of a Highly Sensitive Technique for Capturing Renal Cell Cancer Circulating Tumor Cells. Diagnostics 2019, 9, 96.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop